A rare cutaneous manifestation of immune checkpoint inhibitor therapy

Abstract

Abstract Leukocytoclastic vasculitis can be an uncommon and/or underreported adverse event of immune checkpoint inhibitor therapy, an established cancer treatment option. Differentiation among other cutaneous manifestations of adverse medication reactions—such as Stevens–Johnson syndrome, erythema multiforme, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome—is crucial for guiding management.

Keywords

• Immune checkpoint inhibitor
• leukoclastic vasculitis